Oncology Clinical Trial Report in H&N Cancers - prIME Oncology
Virtual Poster
Virtual Poster

Oncology Clinical Trial Report in H&N Cancers

Putting Key Findings From the 2018 European Oncology Congress Into Practice

Not a member of My prIME? Join now for instant access.

View CME-certified poster presentations and downloadable slides covering the most up-to-date clinical trial data on head & neck (H&N) cancer from the 2018 European Oncology Congress in Munich.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



0.5 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Apr 15, 2019

Expiration Date

Apr 15, 2020

Barbara Burtness, MD

Abstract #LBA8_PR: KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Featured Expert: Barbara Burtness, MD


Abstract #1044O: A phase 1b/2 study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

Featured Expert: Ezra Cohen, MD, FRCPSC, FASCO

  • Barbara Burtness, MD Yale Cancer Center
    New Haven, Connecticut, United States
  • Ezra Cohen, MD, FRCPSC, FASCOUC San Diego Health
    San Diego, California, United States

This activity is specifically designed for physicians, nurses, and other clinicians who are cancer specialists.

After successful completion of this educational activity, participants should be able to:

  • Identify clinical trial data presented at 2018 European Oncology Congress in Munich
  • Incorporate new findings presented in Munich into patient treatment regimens, where applicable

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Merck and Co, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 0.5 hours

To contact Postgraduate Institute for Medicine please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Burtness has disclosed advisory board membership with honoraria from Aduro, Alligator Biosciences, AstraZeneca, Bayer, Genentech/Roche, Merck Sharp & Dohme, and TRM Oncology. She is also on a data safety monitoring board for and with honoraria from IDDI (AstraZeneca/MedImmune). She also received study funding, medical writing, and editorial support from Merck Sharp & Dohme. She also disclosed funding to her institution for research support from Advaxis, Bristol-Myers Squibb, Foundation Biologics, and Merck Sharp & Dohme. She disclosed travel expenses from Boehringer Ingelheim and Merck Sharpe & Dohme. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Cohen has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.